Psychopharmacogenetics

  • Philip Gorwood
  • Michel Hamon

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Philip Gorwood, Elizabeth Foot
    Pages 1-24
  3. Alessandro Serretti, Paola Artioli
    Pages 45-73
  4. Pierre Oswald, Daniel Souery, Julien Mendlewicz
    Pages 75-100
  5. Joachim Scharfetter
    Pages 101-148
  6. Lucie Maréchal, Isabelle Le Ber, Didier Hannequin, Dominique Campion, Alexis Brice
    Pages 149-176
  7. Philip Gorwood, Gunter Schumann, Jens Treutlein, Jean Adès
    Pages 177-201
  8. Mariken de Krom, Annemarie van Elburg, Pierre M. Zelissen, Roger A. H. Adan
    Pages 203-230
  9. Stéphane Jamain, Marion Leboyer
    Pages 249-263
  10. Rolando Meloni, Olfa Khalfallah, Nicole Faucon Biguet
    Pages 265-287
  11. Katerina J. Damjanoska, Louis D. Van de Kar
    Pages 289-332
  12. Mohamed Jaber
    Pages 333-355
  13. Pierre Sokoloff, Ludovic Leriche, Bernard Le Foll
    Pages 357-419
  14. Enrico Sanna, Paolo Follesa, Giovanni Biggio
    Pages 421-442
  15. Marja-Liisa Dahl, Maria Gabriella Scordo
    Pages 443-478
  16. Christopher G. Goetz
    Pages 495-514

About this book

Introduction

Adult and child psychiatric disorders, including mood disorders, psychosis, substance abuse, and dementia, represent a large source of disability in the general population. The urgency to develop new treatments that may have better efficacy and tolerance is explained by the fact that none of the treatments currently available can be considered completely satisfying. Several reasons underlie this relative failure, such as, for example, (1) lack of knowledge of the mechanisms involved, (2) heterogeneity of most psychiatric disorders (that have good inter-rater validity but weak relationship with specific neurobiological mechanisms), (3) variable tolerance that leads to poor compliance, and (4) insufficient prediction for a specific treated patient of the efficacy, side effects, and outcome associated with the prescribed treatments.

Furthermore, from an economical point of view, psychiatric disorders are now the most expensive disorders to treat. The costs associated with mental illnesses, which constitute a significant percentage of the total direct health care costs, are currently estimated above $100 billion (USD), representing $1,605 per person per year in the U.S. (9% of the gross national product).

Prediction of efficacy, prevention of major side effects, and selection of the most appropriate treatment should thus have major medical and economical impacts. The pharmacogenetics devoted to psychotropic drugs (psychopharmacogenetics) will help to further develop these points.

The psychopharmacogenetic field represents an important area of research that is based on various specialties including clinical psychiatry, pharmacology, neurobiology and genetics. However, data issued from such relevant investigations are frequently, for clinicians as for scientists, rather obscure and/or scattered.

In this book, the basic and advanced knowledge on psychiatric disorders will be provided for non-clinicians: What is schizophrenia? What are the risk factors? What are the core symptoms? How is it treated? What are the efficacy and side effects of the available treatments and their mechanisms? Are there already some psychopharmacogenetic data useful in clinical practice?

Keywords

Alzheimer Behavioral Neuroscience attention attention deficit hyperactivity disorder (ADHD) dementia dopamine neurobiology neuropharmacology neuropsychology neuroscience psychiatric disorder psychiatry psychosis research schizophrenia

Editors and affiliations

  • Philip Gorwood
    • 1
  • Michel Hamon
    • 2
  1. 1.Dept. of PsychiatryLouis Mourier HospitalColombesFrance
  2. 2.Faculty of Medicine Pitie-SalpetriereHopital SalpetriereNeurobiolFrance

Bibliographic information

  • DOI https://doi.org/10.1007/0-387-34577-2
  • Copyright Information Springer 2006
  • Publisher Name Springer, Boston, MA
  • eBook Packages Medicine
  • Print ISBN 978-0-387-30793-0
  • Online ISBN 978-0-387-34577-2
  • About this book